Senseonics (SENS) Registration Filing summary

Company overview and business model

• Focuses on developing and manufacturing implantable continuous glucose monitoring (CGM) systems for diabetes management, including Eversense E3 (180-day) and Eversense 365 (365-day) sensors.

• Products offer longer wear time compared to non-implantable CGMs, with real-time monitoring via a smart transmitter and app.

• Commercialization is driven by partnerships, notably with Ascensia Diabetes Care, and a network of distributors and healthcare providers.

• Revenue is primarily from sales of sensor and transmitter kits, with reimbursement from insurance and government payors being critical.

• Strategic focus includes expanding payor coverage and developing next-generation products, such as Gemini (2-in-1 CGM/Flash) and Freedom (Bluetooth-enabled sensor).

Financial performance and metrics

• Has incurred significant operating losses since inception and may not achieve or sustain profitability.

• Results of operations fluctuate significantly quarter to quarter and year to year.

• Substantial future revenue is expected from the commercialization agreement with Ascensia.

• Recurring losses and liquidity concerns raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder; proceeds from warrant exercises (if for cash) will go to the company.

• All registration costs are borne by the company, while selling commissions and discounts are borne by the selling stockholder.